Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Liver-specific deceased donor risk indices.

Wang Z, Hisatake G, Yang L.

Hepatol Res. 2014 Feb;44(2):159-64. doi: 10.1111/hepr.12228. Epub 2013 Oct 18.

PMID:
24033790
2.

De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.

Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.

Liver Transpl. 2001 Jan;7(1):51-8.

3.

Infectivity of hepatic allografts with antibodies to hepatitis B virus.

Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ.

Transplantation. 1997 Dec 15;64(11):1582-4.

PMID:
9415560
4.

Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.

Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG.

Transplantation. 2003 Apr 27;75(8):1179-86.

PMID:
12717200
5.

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.

Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.

Liver Transpl. 2001 Jun;7(6):513-7.

6.

Liver grafts from anti-hepatitis B core positive donors: a systematic review.

Cholongitas E, Papatheodoridis GV, Burroughs AK.

J Hepatol. 2010 Feb;52(2):272-9. doi: 10.1016/j.jhep.2009.11.009. Epub 2010 Jan 19. Review.

7.

Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.

Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J.

Transpl Int. 2006 Jan;19(1):38-43.

PMID:
16359375
8.

Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.

Holt D, Thomas R, Van Thiel D, Brems JJ.

Arch Surg. 2002 May;137(5):572-5; discussion 575-6.

PMID:
11982471
9.

Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results.

Loss GE, Mason AL, Blazek J, Dick D, Lipscomb J, Guo L, Perrillo RP, Eason JD.

Clin Transplant. 2001;15 Suppl 6:55-8.

PMID:
11903388
10.

Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.

Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD.

Liver Transpl. 2003 Dec;9(12):1253-7.

11.

Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis.

Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE.

Transplantation. 2002 May 27;73(10):1598-602.

PMID:
12042646
12.

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.

Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ.

Transplantation. 1999 Oct 15;68(7):1058-61.

PMID:
10532552
13.

Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area.

Ko WJ, Chou NK, Hsu RB, Chen YS, Wang SS, Chu SH, Lai MY.

J Heart Lung Transplant. 2001 Aug;20(8):865-75.

PMID:
11502409
14.

Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.

Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E.

Gut. 2002 Jan;50(1):95-9.

15.

Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts.

Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD.

Liver Transpl. 2006 Oct;12(10):1496-503.

16.

Outcomes of liver transplantation in simultaneously hepatitis B surface antigen and hepatitis C virus RNA positive recipients: the deleterious effect of donor hepatitis B core antibody positivity.

Tandoi F, Romagnoli R, Martini S, Mazza E, Nada E, Cocchis D, Lupo F, Salizzoni M.

Transplant Proc. 2012 Sep;44(7):1960-2. doi: 10.1016/j.transproceed.2012.07.061.

PMID:
22974882
17.

Occult hepatitis B virus infection among Egyptian blood donors.

Said ZN, Sayed MH, Salama II, Aboel-Magd EK, Mahmoud MH, Setouhy ME, Mouftah F, Azzab MB, Goubran H, Bassili A, Esmat GE.

World J Hepatol. 2013 Feb 27;5(2):64-73. doi: 10.4254/wjh.v5.i2.64.

18.

The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD.

Liver Transpl. 2010 Jul;16(7):874-84. doi: 10.1002/lt.22085.

19.

High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.

Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH.

J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):203-8. doi: 10.1097/MPG.0b013e3181819ad4.

PMID:
19179883
20.

Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor.

Yu L, Koepsell T, Manhart L, Ioannou G.

Liver Transpl. 2009 Oct;15(10):1343-50. doi: 10.1002/lt.21788.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk